Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Rini, B. I.; Huseni, M.; Atkins, M. B.; McDermott, D. F.; Powles, T. B.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; Fan, J.; Doss, J.; Nalle, S.; Carroll, S.; Li, S.; Schiff, C.; Green, M.; Motzer, R. J. |
| Abstract Title: | Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy424.037 |
| Language: | English |
| ACCESSION: | WOS:000459277304390 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy424.037 |
| Notes: | Meeting Abstract: LBA31 -- Appears on pages viii724-viii725 of the abstract book -- Source: Wos |
